Jun 21, 2024, 09:47
Blinatumomab alternating with LIC in older adults with newly diagnosed B-ALL – ALL Hub
ALL Hub shared a post on X:
“CONGRESS | POSTER | EHA2024 | Elias Jabbour from MD Anderson Cancer Center reports follow-up for the phase III Golden Gate Study of blinatumomab alternating with low-intensity chemotherapy (LIC) in older adults with ND B-ALL. 13/14 (92.9%) patients had CR with blinatumomab and alternating LIC at the end of induction (~Week 14), 84.6% of these were MRD-negative. Acceptable safety profile.”
Source: ALL Hub/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 12:13
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44
Nov 13, 2024, 11:39
Nov 13, 2024, 11:30
Nov 13, 2024, 11:25
Nov 13, 2024, 11:10
Nov 13, 2024, 10:59